Nuclear Cardiology

Single photon computed tomography (SPECT) and positron emission tomography (PET) molecular imaging are used as primary cardiac imaging modalities to evaluate the function of the heart. It uses radioactive isotopes attached to sugars that are metabolized by cardiomyocytes. This creates an image of the metabolic activity of the heart and shows areas of ischemia or infarct. Other radiotracers can image the heart to diagnosis cardiac amyloidosis and sarcoidosis. 

RSS icon
FAPI PET/CT shows promise as a better radiotracer for cancer than 18F-FDG. It also can be used for detection of infection and inflammation.

VIDEO: 6 key advances in molecular imaging technology for PET and SPECT

Munir Ghesani, MD, President of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), system chief of nuclear medicine at Mount Sinai Health, explains recent advances in nuclear imaging technology.

A study published this week in the Journal of the American College of Cardiology (JACC): Cardiovascular Imaging shows artificial intelligence (AI) algorithms can more rapidly and objectively determine calcium scores in computed tomographic (CT) and positron emission tomographic (PET) images than physicians.[1] The AI also performed well when the images were obtained from very-low-radiation CT attenuation scans. https://doi.org/10.1016/j.jcmg.2022.06.006

Artificial intelligence can objectively determine cardiac calcium scores faster than doctors

A new study shows artificial intelligence (AI) algorithms can more rapidly and objectively determine calcium scores in CT and PET/CT images than physicians.

Thumbnail

Cardiologist compensation hits $622K, up 32% from 10 years ago

According to a new analysis from MedAxiom, an American College of Cardiology company, cardiologist compensation has nearly returned to where it was before the COVID-19 pandemic. The detailed report also examined new patient visits, cardiac imaging utilization and much more. 

Comparison of flurpiridaz F-18 PET, SPECT and angiography of the 60-year-old female patients in the Aurora trial. The SPECT scan appeared normal, but flurpiridaz was shown to be more sensitive and showed the ischemia from two blockages in the right coronary artery. The new radiotracer may help expand cardiac PET. #ASNC

Flurpiridaz data shows promise to expand and enhance cardiac PET

The biggest news from the American Society of Nuclear Cardiology (ASNC) 2022 meeting was positive late-breaking data on the phase 3 Aurora trial for the flurpiridaz (F-18) PET radiotracer agent.

PET imaging uncovers a surprising new way COVID-19 affects the heart

A new study in JACC: Cardiovascular Imaging focuses on a potential new side effect of COVID-19, highlighting the continued importance of monitoring these patients going forward. 

This latest shortage involves dobutamine, an injectable medication often prescribed for advanced heart failure and cardiogenic shock. It is also a central component of dobutamine stress echocardiography (DSE), a test used to evaluate patients with severe aortic stenosis.

A new supply issue hits cardiology: 5 recommendations for cardiologists during the dobutamine shortage

The shortage could lead to significant issues for cardiologists. The American College of Cardiology provided some words of wisdom on the ongoing issue.  

New PET imager cleared for U.S. sales

A Canadian manufacturer of positron emission tomography equipment has received FDA’s OK to market a small-footprint scanner that images targeted organs bearing radiotracers at close range.

Big private payer reverses course on cardiac PET/CT coverage

One of the largest private health insurers in the U.S. has gone from considering hybrid PET/CT for cardiac indications “experimental/investigational” to displaying willingness to pay for the modality. 

Displaying 49 - 56 of 100
Design by Adaptive Theme